Cargando…
Comparison of Anticancer Medication Use and Spending Under US Oncology Parity Laws With and Without Out-of-Pocket Spending Caps
IMPORTANCE: By 2020, nearly all states had adopted oncology parity laws in the US, ensuring that patients in fully insured private health plans pay no more for orally administered anticancer medications (OAMs) than infused therapies. Between 2013 and mid-2017, 11 states implemented parity with out-o...
Autores principales: | Dusetzina, Stacie B., Huskamp, Haiden A., Jazowski, Shelley A., Winn, Aaron N., Basch, Ethan, Keating, Nancy L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796987/ https://www.ncbi.nlm.nih.gov/pubmed/35977314 http://dx.doi.org/10.1001/jamahealthforum.2021.0673 |
Ejemplares similares
-
Out-of-Pocket Spending Not Associated with Oral Oncolytic Survival Benefit
por: Rotenstein, Lisa S., et al.
Publicado: (2018) -
Was federal parity associated with changes in Out-of-network mental health care use and spending?
por: Busch, Susan H., et al.
Publicado: (2017) -
The effects of oral anticancer parity laws on out-of-pocket spending and adherence among commercially insured patients with chronic myeloid leukemia
por: Spargo, Andrew, et al.
Publicado: (2021) -
Evaluation of Trends in Oncology Drug Spending in Medicare, 2016 to 2020
por: Kyle, Michael Anne, et al.
Publicado: (2022) -
Assessment of Expected Out-of-Pocket Spending for Rheumatoid Arthritis Biologics Among Patients Enrolled in Medicare Part D, 2010-2019
por: Erath, Alexandra, et al.
Publicado: (2020)